How effective is fenelidone in reducing urinary protein?

Urine protein is an important marker of the progression of chronic kidney disease (CKD). An increase in proteinuria often indicates impaired renal function, and the higher the proteinuria level, the greater the risk of kidney disease progressing to end-stage renal disease (ESRD). Finerenone As a non-steroidal selective MR antagonist, it can effectively reduce proteinuria and reduce the risk of renal function deterioration.

Multiple clinical studies have shown that fenelidone has significant efficacy in reducing urinary protein excretion, especially for patients with type 2 diabetes and chronic kidney disease (CKD stage 3-4, accompanied by proteinuria). It can effectively reduce the urinary protein-to-creatinine ratio (UACR) and reduce the risk of kidney disease progression.

Clinical research data supports:

1. FIDELIO-DKD study: This large clinical trial shows that treatment with fenelinone can reduce patients' urine protein-to-creatinine ratio (UACR) by about 30% on average, and significantly reduce the progression of renal disease and the incidence of end-stage renal disease.

2. FIGARO-DKD study: further confirmed the cardiovascular protective effect of fenelinone, and also showed its sustained efficacy in reducing proteinuria.

Mechanism of action analysis:

1. By blocking the activation of MR receptors, it reduces renal tubulointerstitial fibrosis and inflammatory response, thereby improving renal microcirculation and reducing proteinuria.

2. Protect glomerular integrity and prevent protein leakage by reducing aldosterone-induced vascular damage.

3. By reducing oxidative stress and inflammatory response in the kidney, it improves kidney function and delays the progression of CKD.

Fennelidone can not only significantly reduce proteinuria, but also reduce the risk of renal disease progression and provide protection for the cardiovascular system. It is an important innovative treatment option for patients with chronic kidney disease and diabetes. However, patients need to regularly monitor blood potassium levels during medication to avoid the occurrence of hyperkalemia.

Reference materials:https://www.kerendia.com/